Molecular Biology

, Volume 53, Issue 3, pp 427–437 | Cite as

Characterization of Distal and Proximal Alternative Promoters of the Human ApoA-I Gene

  • D. A. Mogilenko
  • V. S. Shavva
  • E. B. Dizhe
  • S. V. OrlovEmail author


Human apolipoprotein A-I (ApoA-I) is a major structural and functional protein component of high-density lipoprotein (HDL). ApoA-I constitutes ~75% of the protein content of HDL. The main sites of ApoA-I synthesis in humans are the liver and the small intestine. The mechanisms that govern tissue-specific apoA-I transcription in tissues and organs other than the liver and the small intestine are poorly understood. It is known that the human apoA-I has two additional promoters, the proximal and the distal one. In this work these two alternative apoA-I promoters are characterized, their transcription start sites are mapped and their competition for apoA-I transcription is demonstrated; the role of the alternative promoters in apoA-I expression in human cells and tissues other than hepatocytes and enterocytes is discussed.


apolipoprotein A-I alternative promoter promoter competition transcription start site human hepatoma cells HepG2 



  1. 1.
    Gordon D.J., Probstfield J.L., Garrison R.J., Neaton J.D., Castelli W.P., Knoke J.D., Jacobs D.RJ., Bangdiwala S., Tyroler H.A. 1989. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 79, 8‒15.CrossRefGoogle Scholar
  2. 2.
    Stein O., Stein Y. 1999. Atheroprotective mechanisms of HDL. Atherosclerosis. 144, 85‒301.Google Scholar
  3. 3.
    Eggerman T.L., Hoeg J.M., Meng M.S., Tombragel A., Bojanovski D., Brewer H.BJ. 1991. Differential tissue-specific expression of human apoA-I and apoA-II. J. Lipid Res. 32, 821–828.Google Scholar
  4. 4.
    Srivastava R.A., Srivastava N. 2000. High density lipoprotein, apolipoprotein A-I, and coronary artery disease. Mol. Cell. Biochem. 209, 131‒144.CrossRefGoogle Scholar
  5. 5.
    Higuchi K., Law S.W., Hoeg J.M., Schumacher U.K., Meglin N., Brewer H.B.J. 1988. Tissue-specific expression of apolipoprotein A-I (ApoA-I) is regulated by the 5'-flanking region of the human ApoA-I gene. J. Biol. Chem. 263, 18530‒18536.Google Scholar
  6. 6.
    Sastry K.N., Seedorf U., Karathanasis S.K. 1988. Different cis-acting DNA elements control expression of the human apolipoprotein AI gene in different cell types. Mol. Cell. Biol. 8, 605‒614.CrossRefGoogle Scholar
  7. 7.
    Kardassis D., Laccotripe M., Talianidis I., Zannis V. 1996. Transcriptional regulation of the genes involved in lipoprotein transport. The role of proximal promoters and long-range regulatory elements and factors in apolipoprotein gene regulation. Hypertension. 27, 980‒1008.CrossRefGoogle Scholar
  8. 8.
    Kardassis D., Tzameli I., Hadzopoulou-Cladaras M., Talianidis I., Zannis V. 1997. Distal apolipoprotein C-III regulatory elements F to J act as a general modular enhancer for proximal promoters that contain hormone response elements. Synergism between hepatic nuclear factor-4 molecules bound to the proximal promoter and distal enhancer sites. Arterioscler. Thromb. Vasc. Biol. 17, 222‒232.CrossRefGoogle Scholar
  9. 9.
    Tzameli I., Zannis V.I. 1996. Binding specificity and modulation of the ApoA-I promoter activity by homo- and heterodimers of nuclear receptors. J. Biol. Chem. 271, 8402‒8415.CrossRefGoogle Scholar
  10. 10.
    Harnish D.C., Malik S., Kilbourne E., Costa R., Karathanasis S.K. 1996. Control of apolipoprotein AI gene expression through synergistic interactions between hepatocyte nuclear factors 3 and 4. J. Biol. Chem. 271, 13621‒13628.CrossRefGoogle Scholar
  11. 11.
    Martin C., Duez H., Blanquart C., Berezowski V., Poulain P., Fruchart J.-C., Najib-Fruchart J., Glineur C., Staels B. 2001. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J. Clin. Invest. 107, 1423–1432.CrossRefGoogle Scholar
  12. 12.
    Delerive P., Galardi C.M., Bisi J.E., Nicodeme E., Goodwin B. 2004. Identification of liver receptor homolog-1 as a novel regulator of apolipoprotein AI gene transcription. Mol. Endocrinol. 18, 2378‒2387.CrossRefGoogle Scholar
  13. 13.
    Huuskonen J., Vishnu M., Chau P., Fielding P.E., Fielding C.J. 2006. Liver X receptor inhibits the synthesis and secretion of apolipoprotein A1 by human liver-derived cells. Biochemistry. 45, 15068‒15074.CrossRefGoogle Scholar
  14. 14.
    Claudel T., Sturm E., Duez H., Torra I.P., Sirvent A., Kosykh V., Fruchart J., Dallongeville J., Hum D.W., Kuipers F., Staels B. 2002. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J. Clin. Invest. 109, 961‒971.CrossRefGoogle Scholar
  15. 15.
    Shavva V.S., Mogilenko D.A., Bogomolova A.M., Nikitin A.A., Dizhe E.B., Efremov A.M., Oleinikova G.N., Perevozchikov A.P., Orlov S.V. 2016. PPARgamma represses apolipoprotein A-I gene but impedes TNFalpha-mediated ApoA-I downregulation in HepG2 cells. J. Cell. Biochem. 117, 2010‒2022.CrossRefGoogle Scholar
  16. 16.
    Kilbourne E.J., Evans M.J., Karathanasis S.K. 1998. E1A represses apolipoprotein AI enhancer activity in liver cells through a pRb- and CBP-independent pathway. Nucleic Acids Res. 26, 1761‒1768.CrossRefGoogle Scholar
  17. 17.
    Shavva V.S., Bogomolova A.M., Nikitin A.A., Dizhe E.B., Tanyanskiy D.A., Efremov A.M., Oleinikova G.N., Perevozchikov A.P., Orlov S.V. 2017. Insulin-mediated downregulation of apolipoprotein A-I gene in human hepatoma cell line HepG2: the role of interaction between FOXO1 and LXRbeta transcription factors. J. Cell. Biochem. 118, 382‒396.CrossRefGoogle Scholar
  18. 18.
    Shavva V.S., Bogomolova A.M., Nikitin A.A., Dizhe E.B., Oleinikova G.N., Lapikov I.A., Tanyanskiy D.A., Perevozchikov A.P., Orlov S.V. 2017. FOXO1 and LXRalpha downregulate the apolipoprotein A-I gene expression during hydrogen peroxide-induced oxidative stress in HepG2 cells. Cell Stress Chaperones. 22, 123‒134.CrossRefGoogle Scholar
  19. 19.
    Kilbourne E.J., Widom R., Harnish D.C., Malik S., Karathanasis S.K. 1995. Involvement of early growth response factor Egr-1 in apolipoprotein AI gene transcription. J. Biol. Chem. 270, 7004‒7010.CrossRefGoogle Scholar
  20. 20.
    Richardson B., Palgunachari M.N., Anantharamaiah G.M., Richards R.G., Azrolan N., Wiginton D., Handwerger S. 1996. Human placental tissue expresses a novel 22.7 kDa apolipoprotein A-I-like protein. Biochemistry. 35, 7580‒7585.CrossRefGoogle Scholar
  21. 21.
    Baroukh N., Lopez C.E., Saleh M.C., Recalde D., Vergnes L., Ostos M.A., Fiette L.J., Fruchart C., Castro G., Zakin M.M., Ochoa A. 2004. Expression and secretion of human apolipoprotein A-I in the heart. FEBS Lett. 557, 39‒44.CrossRefGoogle Scholar
  22. 22.
    Gentili C., Tutolo G., Pianezzi A., Cancedda R., Descalzi C.F. 2005. Cholesterol secretion and homeostasis in chondrocytes: a liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein A1 expression. Matrix Biol. 24, 35‒44.CrossRefGoogle Scholar
  23. 23.
    Vorob'ev E.V., Perevozchikov A.P. 1992. Analysis of apolipoprotein A-I gene expression at early stages of human ontogeny using in situ hybridization. Ontogenez. 23, 469‒479.Google Scholar
  24. 24.
    Mogilenko D.A., Orlov S.V., Trulioff A.S., Ivanov A.V., Nagumanov V.K., Kudriavtsev I.V., Shavva V.S., Tanyanskiy D.A., Perevozchikov A.P. 2012. Endogenous apolipoprotein A-I stabilizes ATP-binding cassette transporter A1 and modulates Toll-like receptor 4 signaling in human macrophages. FASEB J. 26, 2019‒2030.CrossRefGoogle Scholar
  25. 25.
    Shavva V.S., Mogilenko D.A., Nekrasova E.V., Trulioff A.S., Kudriavtsev I.V., Larionova E.E., Babina A.V., Dizhe E.B., Missyul B.V., Orlov S.V. 2018. Tumor necrosis factor alpha stimulates endogenous apolipoprotein A-I expression and secretion by human monocytes and macrophages: Role of MAP-kinases, NF-kB, and nuclear receptors PPARalpha and LXRs. Mol. Cell. Biochem. 448, 211‒223.CrossRefGoogle Scholar
  26. 26.
    Orlov S.V., Mogilenko D.A., Shavva V.S., Dizhe E.B., Ignatovich I.A., Perevozchikov A.P. 2010. Effect of TNFalpha on activities of different promoters of human apolipoprotein A-I gene. Biochem. Biophys. Res. Commun. 398, 224‒230.CrossRefGoogle Scholar
  27. 27.
    Mogilenko D.A., Kudriavtsev I. V., Trulioff A.S., Shavva V.S., Dizhe E.B., Missyul B.V., Zhakhov A.V., Ischenko A.M., Perevozchikov A.P., Orlov S.V. 2012. Modified low density lipoprotein stimulates complement C3 expression and secretion via liver X receptor and toll-like receptor 4 activation in human macrophages. J. Biol. Chem. 287, 5954‒5968.CrossRefGoogle Scholar
  28. 28.
    Mogilenko D.A., Kudriavtsev I.V., Shavva V.S., Dizhe E.B., Vilenskaya E.G., Efremov A. M., Perevozchikov A.P., Orlov S.V. 2013. Peroxisome proliferator-activated receptor alpha positively regulates complement C3 expression but inhibits TNFalpha-mediated activation of C3 gene in mammalian hepatic derived cells. J. Biol. Chem. 288, 1726‒1738.CrossRefGoogle Scholar
  29. 29.
    Lapikov I.A., Mogilenko D.A., Dizhe E.B., Ignatovich I.A., Orlov S.V. Perevozchikov A.P. 2008. Ap1-like cis elements in the 5'-regulatory region of the human apolipoprotein A-I gene. Mol. Biol. (Moscow). 42 (2), 261‒269.CrossRefGoogle Scholar
  30. 30.
    Graham F.L., van der Eb A.J. 1973. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology. 52, 456‒467.CrossRefGoogle Scholar
  31. 31.
    Reisher S.R., Hughes T.E., Ordovas J M., Schaefer E.J., Feinstein S.I. 1993. Increased expression of apolipoprotein genes accompanies differentiation in the intestinal cell line Caco-2. Proc. Natl. Acad. Sci. U. S. A. 90, 5757‒5761.CrossRefGoogle Scholar
  32. 32.
    Kozak M. 1997. Recognition of AUG and alternative initiator codons is augmented by G in position +4 but is not generally affected by the nucleotides in positions +5 and +6. EMBO J. 16, 2482‒2492.CrossRefGoogle Scholar
  33. 33.
    Halley P., Kadakkuzha B.M., Faghihi M. A., Magistri M., Zeier Z., Khorkova O., Coito C., Hsiao J., Lawrence M., Wahlestedt C. 2014. Regulation of the apolipoprotein gene cluster by a long noncoding RNA. Cell Rep. 6, 222‒230.CrossRefGoogle Scholar

Copyright information

© Pleiades Publishing, Inc. 2019

Authors and Affiliations

  • D. A. Mogilenko
    • 1
    • 2
    • 3
  • V. S. Shavva
    • 1
  • E. B. Dizhe
    • 1
  • S. V. Orlov
    • 1
    • 2
    Email author
  1. 1.Institute of Experimental MedicineSt. PetersburgRussia
  2. 2.St. Petersburg State UniversitySt. PetersburgRussia
  3. 3.Université de Lille, Inserm, Institut Pasteur de LilleLilleFrance

Personalised recommendations